CN115350116A - Oral cavity antibacterial cream and preparation method and application thereof - Google Patents
Oral cavity antibacterial cream and preparation method and application thereof Download PDFInfo
- Publication number
- CN115350116A CN115350116A CN202211144923.5A CN202211144923A CN115350116A CN 115350116 A CN115350116 A CN 115350116A CN 202211144923 A CN202211144923 A CN 202211144923A CN 115350116 A CN115350116 A CN 115350116A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- oral
- modified chitosan
- oral bacteriostatic
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/50—Preparations specially adapted for dental root treatment
- A61K6/52—Cleaning; Disinfecting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
- A61K6/69—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/70—Preparations for dentistry comprising inorganic additives
- A61K6/71—Fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an oral cavity antibacterial cream and a preparation method and application thereof, wherein the oral cavity antibacterial cream comprises calcium hydroxide, modified chitosan, vaseline and lanolin; the modified chitosan is chitosan grafted alkyl glycoside quaternary ammonium salt. The oral bacteriostatic paste has good stability, has a continuous bactericidal effect, and effectively avoids the early absorption and diffusion of calcium hydroxide.
Description
Technical Field
The invention relates to the technical field of oral cleaning products, in particular to an oral bacteriostatic cream and a preparation method and application thereof.
Background
The root canal therapy of teeth is the operation for treating pulp necrosis and root infection at present, and the key to successful treatment lies in clearing away the microorganisms and metabolites in the root canal and creating an environment which is not beneficial to the survival of the microorganisms.
The endodontic procedure includes three stages of root canal preparation, disinfection and filling. Due to the complexity of the root canal system, the conventional mechanical preparation can only remove most infected tissues and cannot completely remove the infected tissues, and bacteria and toxins remaining in deep dentinal tubules and side branch root canals are still difficult to remove by only depending on manual instruments or machine nickel titanium instruments, so the root canal sterilization plays a key role.
The existing root canal disinfection drugs are various and comprise calcium hydroxide, iodoform and silicone oil. Patent No. CN111000731A discloses a calcium hydroxide-iodoform deciduous tooth root canal filling material, which is prone to secondary infection because calcium oxide often causes phenomena of absorption and diffusion in the root canal in advance, and thus the long-term sterilization and disinfection effect cannot be maintained.
Disclosure of Invention
In view of the above, the invention provides a long-acting bactericidal oral bacteriostatic cream, and a preparation method and application thereof.
The technical scheme of the invention is realized as follows: in a first aspect, the invention provides an oral bacteriostatic cream comprising calcium hydroxide, modified chitosan, vaseline and lanolin; the modified chitosan is chitosan grafted alkyl glycoside quaternary ammonium salt.
On the basis of the technical scheme, preferably, the oral bacteriostatic cream comprises the following components in parts by weight: 20-30 parts of calcium hydroxide, 3-5 parts of modified chitosan, 15-20 parts of vaseline and 20-30 parts of lanolin.
On the basis of the technical scheme, the curcumin-asiaticoside composition preferably further comprises 0.5-1 part by weight of curcumin and 1-2 parts by weight of asiaticoside.
On the basis of the above technical scheme, preferably, the preparation method of the modified chitosan comprises the following steps:
s1, adding chitosan into a reaction vessel, adding an acetic acid solution, uniformly stirring, and adjusting the pH value of the solution to 8-10 to obtain alkalized chitosan;
s2, adding isopropanol into the alkalized chitosan, uniformly stirring, adding alkyl glycoside quaternary ammonium salt, heating to 80-90 ℃, and reacting for 4-6h;
and S3, after the reaction is finished, filtering and vacuum drying to obtain the modified chitosan.
On the basis of the above technical scheme, preferably, in step S3, after the reaction is finished, washing with acetone for 1-3 times, then filtering, and vacuum drying to obtain the modified chitosan.
On the basis of the above technical solution, preferably, the chitosan: acetic acid solution: the mass ratio of the alkyl glycoside quaternary ammonium salt is 1 (15-20) to 0.1-0.3, and the acetic acid solution is 0.3-0.5% by mass of acetic acid aqueous solution.
On the basis of the above technical scheme, preferably, the ratio of isopropanol: the mass ratio of the alkalized chitosan is (10-15): 1.
On the basis of the technical scheme, preferably, the weight average molecular weight of the modified chitosan is 1000-5000.
In a second aspect, the invention provides a preparation method of an oral cavity antibacterial cream, which comprises the following steps:
s1, adding modified chitosan into deionized water, and uniformly stirring to form a colloidal solution;
s2, adding calcium hydroxide, curcumin and asiaticoside into the colloidal solution, uniformly stirring, and adjusting the pH value to 7-8 to obtain a colloidal mixed solution;
and S3, carrying out suction filtration on the colloid mixed liquor, drying, and uniformly mixing with vaseline and lanolin at the temperature of 20-30 ℃ to obtain the oral bacteriostatic cream.
In a third aspect, the invention provides an application of the oral cavity antibacterial paste in root canal disinfection.
Compared with the prior art, the oral bacteriostatic cream and the preparation method and application thereof have the following beneficial effects:
(1) In the oral cavity antibacterial paste, the chitosan coats the calcium hydroxide, so that the drug effect of the calcium hydroxide is slowly released and the calcium hydroxide is continuously sterilized, and the phenomena of advanced absorption and diffusion of the calcium hydroxide are effectively avoided; the quaternary ammonium salt of alkyl glycoside modified chitosan has raised permeability and raised medicine effect.
(2) Asiaticoside has effects of promoting wound healing, inhibiting formation of skin scar, resisting tumor, fibrosis, nerve protection, anxiety, depression, inflammation and lung protection. Curcumin has effects of reducing blood lipid, resisting oxidation, resisting inflammation, resisting atherosclerosis, and resisting tumor. In the application, the asiaticoside is matched with curcumin to have stronger bactericidal action on enterococcus faecalis.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments of the present invention, belong to the protection scope of the present invention.
The materials and reagents used in the invention are all commercial reagents, the asiaticoside raw material medicine is purchased from Guangxi Changzhou natural medicine industry limited company, and the purity is as follows: more than or equal to 60 percent; curcumin was purchased from Donreisi Biotechnology Ltd with a purity of > 98%.
Example 1
The oral bacteriostatic paste of the embodiment comprises: 20g of calcium hydroxide, 3g of modified chitosan, 15g of vaseline and 20g of lanolin.
The preparation method of the modified chitosan comprises the following steps:
s1, adding 1g of chitosan into a reaction container, adding 15g of acetic acid aqueous solution with the mass fraction of 0.3%, uniformly stirring, adding NaOH to adjust the pH value of the solution to 8, and obtaining alkalized chitosan;
s2, adding 10 times of isopropanol into the alkalized chitosan, uniformly stirring, adding 0.1g of alkyl glycoside quaternary ammonium salt, heating to 80 ℃, and reacting for 4 hours;
and S3, after the reaction is finished, washing the mixture for 1 time by using acetone, and then filtering and vacuum drying the mixture to obtain the modified chitosan.
The preparation method of the oral bacteriostatic paste comprises the following steps:
s1, adding modified chitosan into deionized water, and uniformly stirring to form a colloidal solution;
s2, adding calcium hydroxide into the colloidal solution, uniformly stirring, and adjusting the pH value to 7 to obtain a colloidal mixed solution;
and S3, carrying out suction filtration on the colloid mixed liquor, drying, and then uniformly mixing with vaseline and lanolin at the temperature of 20 ℃ to obtain the oral bacteriostatic cream.
Example 2
The oral bacteriostatic cream of the embodiment comprises: 22g of calcium hydroxide, 3.5g of modified chitosan, 0.5g of curcumin, 1.5g of asiaticoside, 16g of vaseline and 22g of lanolin.
The preparation method of the modified chitosan comprises the following steps:
s1, adding 1g of chitosan into a reaction container, adding 16g of acetic acid aqueous solution with the mass fraction of 0.4%, uniformly stirring, adding NaOH to adjust the pH value of the solution to 9, and obtaining alkalized chitosan;
s2, adding isopropanol with the mass being 12 times that of the alkalized chitosan into the alkalized chitosan, uniformly stirring, adding 0.2g of alkyl glycoside quaternary ammonium salt, heating to 85 ℃, and reacting for 4.5 hours;
and S3, after the reaction is finished, washing the mixture for 2 times by using acetone, and then filtering and drying the mixture in vacuum to obtain the modified chitosan.
The preparation method of the oral bacteriostatic paste comprises the following steps:
s1, adding modified chitosan into deionized water, and uniformly stirring to form a colloidal solution;
s2, adding calcium hydroxide, curcumin and asiaticoside into the colloidal solution, uniformly stirring, and adjusting the pH value to 7.5 to obtain a colloidal mixed solution;
and S3, carrying out suction filtration on the colloid mixed liquor, drying, and then uniformly mixing with vaseline and lanolin at 25 ℃ to obtain the oral bacteriostatic cream.
Example 3
The oral bacteriostatic cream of the embodiment comprises: 24g of calcium hydroxide, 4g of modified chitosan, 0.6g of curcumin, 1.8g of asiaticoside, 18g of vaseline and 25g of lanolin.
The preparation method of the modified chitosan comprises the following steps:
s1, adding 1g of chitosan into a reaction container, adding 18g of acetic acid aqueous solution with the mass fraction of 0.4%, uniformly stirring, adding NaOH to adjust the pH value of the solution to 9, and obtaining alkalized chitosan;
s2, adding 13 times of isopropanol by mass into the alkalized chitosan, adding into the alkalized chitosan, uniformly stirring, adding 0.2g of alkyl glycoside quaternary ammonium salt, heating to 85 ℃, and reacting for 5 hours;
and S3, after the reaction is finished, washing the mixture for 3 times by using acetone, and then filtering and drying the mixture in vacuum to obtain the modified chitosan.
The preparation method of the oral bacteriostatic paste comprises the following steps:
s1, adding modified chitosan into deionized water, and uniformly stirring to form a colloidal solution;
s2, adding calcium hydroxide, curcumin and asiaticoside into the colloidal solution, uniformly stirring, and adjusting the pH value to 8 to obtain a colloidal mixed solution;
and S3, carrying out suction filtration on the colloid mixed liquor, drying, and then uniformly mixing with vaseline and lanolin at the temperature of 28 ℃ to obtain the oral bacteriostatic cream.
Example 4
The oral bacteriostatic cream of the embodiment comprises: 28g of calcium hydroxide, 4.5g of modified chitosan, 0.8g of curcumin, 1.8g of asiaticoside, 19g of vaseline and 27g of lanolin.
The preparation method of the modified chitosan comprises the following steps:
s1, adding 1g of chitosan into a reaction container, adding 18g of acetic acid aqueous solution with the mass fraction of 0.45%, uniformly stirring, adding NaOH to adjust the pH value of the solution to 9.5, and obtaining alkalized chitosan;
s2, adding isopropanol with the mass being 14 times that of the alkalized chitosan into the alkalized chitosan, uniformly stirring, adding 0.28g of alkyl glycoside quaternary ammonium salt, heating to 88 ℃, and reacting for 5 hours;
and S3, after the reaction is finished, washing the mixture for 3 times by using acetone, and then filtering and drying the mixture in vacuum to obtain the modified chitosan.
The preparation method of the oral bacteriostatic paste comprises the following steps:
s1, adding modified chitosan into deionized water, and uniformly stirring to form a colloidal solution;
s2, adding calcium hydroxide, curcumin and asiaticoside into the colloidal solution, uniformly stirring, and adjusting the pH value to 8 to obtain a colloidal mixed solution;
and S3, carrying out suction filtration on the colloid mixed liquor, drying, and then uniformly mixing with vaseline and lanolin at the temperature of 30 ℃ to obtain the oral bacteriostatic cream.
Example 5
The oral bacteriostatic cream of the embodiment comprises: 30g of calcium hydroxide, 5g of modified chitosan, 1g of curcumin, 2g of asiaticoside, 20g of vaseline and 30g of lanolin.
The preparation method of the modified chitosan comprises the following steps:
s1, adding 1g of chitosan into a reaction container, adding 20g of acetic acid aqueous solution with the mass fraction of 0.5%, uniformly stirring, adding NaOH to adjust the pH value of the solution to 10, and obtaining alkalized chitosan;
s2, adding isopropanol 15 times the mass of the alkalized chitosan into the alkalized chitosan, uniformly stirring, adding 0.3g of alkyl glycoside quaternary ammonium salt, heating to 90 ℃, and reacting for 6 hours;
and S3, after the reaction is finished, washing the mixture for 3 times by using acetone, and then filtering and drying the mixture in vacuum to obtain the modified chitosan.
The preparation method of the oral bacteriostatic paste comprises the following steps:
s1, adding modified chitosan into deionized water, and uniformly stirring to form a colloidal solution;
s2, adding calcium hydroxide and asiaticoside into the colloidal solution, uniformly stirring, and adjusting the pH value to 8 to obtain a colloidal mixed solution;
and S3, carrying out suction filtration on the colloid mixed liquor, drying, and then uniformly mixing with vaseline and lanolin at the temperature of 30 ℃ to obtain the oral bacteriostatic cream.
Comparative example 1
The oral bacteriostatic paste and the preparation method of comparative example 1 are the same as example 1 except that chitosan is not modified.
Comparative example 2
The oral bacteriostatic paste of comparative example 2 and the preparation method were the same as example 1 except that chitosan was absent.
Bacteriostasis test
The cavity bacteriostatic pastes of the examples and the comparative examples were tested for the bactericidal effects on staphylococcus aureus, escherichia coli, enterococcus faecalis and candida albicans, and the results are shown in table 1, wherein the data in table 1 are the average values of three results.
TABLE 1 antibacterial effect of oral cavity antibacterial cream
As shown in Table 1, the bacteriostatic rate of the modified chitosan in examples 1-5 is more than 97%, and the modified chitosan still maintains good bactericidal effect with the time, which indicates that the addition of the modified chitosan makes the drug effect more durable and the bacteriostatic effect better. Compared with examples 1-5, comparative example 1 has a poorer bactericidal effect, which shows that the chitosan modified has enhanced solubility and improved drug effect.
The comparative example 2 has good bactericidal effect in the initial stage, and the bactericidal effect gradually weakens with the time, which shows that the efficacy of the calcium hydroxide is released in advance and the efficacy gradually weakens in the later stage. The oral bacteriostatic paste added with the curcumin and the asiaticoside has higher bacteriostatic rate on the enterococcus faecalis, and shows that the curcumin and the asiaticoside have enhanced bactericidal action on the enterococcus faecalis.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (10)
1. An oral cavity antibacterial cream is characterized in that: including calcium hydroxide, modified chitosan, petrolatum and lanolin; the modified chitosan is chitosan grafted alkyl glycoside quaternary ammonium salt.
2. The oral bacteriostatic cream of claim 1, wherein: the oral bacteriostatic paste comprises the following components in parts by weight: 20-30 parts of calcium hydroxide, 3-5 parts of modified chitosan, 15-20 parts of vaseline and 20-30 parts of lanolin.
3. The oral bacteriostatic cream according to claim 2, characterized in that: also comprises 0.5-1 weight part of curcumin and 1-2 weight parts of asiaticoside.
4. The oral bacteriostatic cream of claim 1, wherein: the preparation method of the modified chitosan comprises the following steps:
s1, adding chitosan into a reaction vessel, adding an acetic acid solution, uniformly stirring, and adjusting the pH value of the solution to 8-10 to obtain alkalized chitosan;
s2, adding isopropanol into the alkalized chitosan, uniformly stirring, adding alkyl glycoside quaternary ammonium salt, heating to 80-90 ℃, and reacting for 4-6h;
and S3, after the reaction is finished, filtering and vacuum drying to obtain the modified chitosan.
5. The oral bacteriostatic cream according to claim 4, characterized in that: in the step S3, after the reaction is finished, washing the mixture for 1 to 3 times by using acetone, and then filtering and vacuum drying the mixture to obtain the modified chitosan.
6. The oral bacteriostatic cream according to claim 4, characterized in that: the chitosan: acetic acid solution: the mass ratio of the alkyl glycoside quaternary ammonium salt is 1 (15-20) to 0.1-0.3, and the acetic acid solution is 0.3-0.5% by mass of acetic acid aqueous solution.
7. The oral bacteriostatic cream according to claim 4, characterized in that: the isopropanol comprises the following components: the mass ratio of the alkalized chitosan is (10-15): 1.
8. The oral bacteriostatic cream according to claim 4, wherein: the weight average molecular weight of the modified chitosan is 1000-5000.
9. A method for preparing an oral bacteriostatic cream according to any one of claims 3 to 8, which is characterized by comprising the following steps: the method comprises the following steps:
s1, adding modified chitosan into deionized water, and uniformly stirring to form a colloidal solution;
s2, adding calcium hydroxide, curcumin and asiaticoside into the colloidal solution, uniformly stirring, and adjusting the pH value to 7-8 to obtain a colloidal mixed solution;
and S3, carrying out suction filtration on the colloid mixed liquor, drying, and uniformly mixing with vaseline and lanolin at the temperature of 20-30 ℃ to obtain the oral bacteriostatic cream.
10. Use of an oral bacteriostatic cream according to any one of claims 1 to 8 for root canal disinfection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211144923.5A CN115350116A (en) | 2022-09-20 | 2022-09-20 | Oral cavity antibacterial cream and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211144923.5A CN115350116A (en) | 2022-09-20 | 2022-09-20 | Oral cavity antibacterial cream and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115350116A true CN115350116A (en) | 2022-11-18 |
Family
ID=84006566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211144923.5A Pending CN115350116A (en) | 2022-09-20 | 2022-09-20 | Oral cavity antibacterial cream and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115350116A (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3879376A (en) * | 1971-05-10 | 1975-04-22 | Oreal | Chitosan derivative, method of making the same and cosmetic composition containing the same |
| WO1999001479A1 (en) * | 1997-07-03 | 1999-01-14 | National Starch And Chemical Investment Holding Corporation | Chitosan derivatives and methods of manufacturing the same |
| US20010053803A1 (en) * | 2000-02-03 | 2001-12-20 | Kao Corporation | Polymer emulsion and process for preparing the same |
| WO2006005211A1 (en) * | 2004-07-12 | 2006-01-19 | Gaba International Ag | Oral hygiene agents containing a chitosan derivative |
| US20140114055A1 (en) * | 2011-02-07 | 2014-04-24 | Hyun-Su Lee | Multifunctional chitosan grafted surfaces and uses thereof |
| CN106496357A (en) * | 2016-10-27 | 2017-03-15 | 山东师范大学 | A kind of O quaternary ammonium salts N alkylated chitosans and preparation method and application |
| CN110240664A (en) * | 2019-07-01 | 2019-09-17 | 北京化工大学 | A kind of preparation method and product of antibacterial chitosan quaternary ammonium salt |
| CN111000731A (en) * | 2019-12-26 | 2020-04-14 | 南昌大学附属口腔医院(江西省口腔医院) | Deciduous tooth root canal filling material and preparation method thereof |
| CN113598178A (en) * | 2021-08-18 | 2021-11-05 | 太和县芮欣生物科技有限公司 | Alkyl glycoside biological bacteriostatic agent and preparation process thereof |
| CN113795236A (en) * | 2019-05-10 | 2021-12-14 | 日本齿科药品株式会社 | Root canal filling material composition |
| CN114984211A (en) * | 2022-05-16 | 2022-09-02 | 青岛大学 | Novel nanoparticles, preparation method and application thereof |
-
2022
- 2022-09-20 CN CN202211144923.5A patent/CN115350116A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3879376A (en) * | 1971-05-10 | 1975-04-22 | Oreal | Chitosan derivative, method of making the same and cosmetic composition containing the same |
| WO1999001479A1 (en) * | 1997-07-03 | 1999-01-14 | National Starch And Chemical Investment Holding Corporation | Chitosan derivatives and methods of manufacturing the same |
| US20010053803A1 (en) * | 2000-02-03 | 2001-12-20 | Kao Corporation | Polymer emulsion and process for preparing the same |
| WO2006005211A1 (en) * | 2004-07-12 | 2006-01-19 | Gaba International Ag | Oral hygiene agents containing a chitosan derivative |
| US20140114055A1 (en) * | 2011-02-07 | 2014-04-24 | Hyun-Su Lee | Multifunctional chitosan grafted surfaces and uses thereof |
| CN106496357A (en) * | 2016-10-27 | 2017-03-15 | 山东师范大学 | A kind of O quaternary ammonium salts N alkylated chitosans and preparation method and application |
| CN113795236A (en) * | 2019-05-10 | 2021-12-14 | 日本齿科药品株式会社 | Root canal filling material composition |
| CN110240664A (en) * | 2019-07-01 | 2019-09-17 | 北京化工大学 | A kind of preparation method and product of antibacterial chitosan quaternary ammonium salt |
| CN111000731A (en) * | 2019-12-26 | 2020-04-14 | 南昌大学附属口腔医院(江西省口腔医院) | Deciduous tooth root canal filling material and preparation method thereof |
| CN113598178A (en) * | 2021-08-18 | 2021-11-05 | 太和县芮欣生物科技有限公司 | Alkyl glycoside biological bacteriostatic agent and preparation process thereof |
| CN114984211A (en) * | 2022-05-16 | 2022-09-02 | 青岛大学 | Novel nanoparticles, preparation method and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| KR HOLME，LD HALL: "Chitosan derivatives bearing C10-alkyl glycoside branches: a temperature-induced gelling polysaccharide", MACROMOLECULES, vol. 24, no. 13, pages 3828 - 3833 * |
| 张文茹等: "壳聚糖乳牙根管用药的疗效观察", 现代中西医结合杂志, vol. 22, no. 28, pages 3163 - 3165 * |
| 张胜华等: "积雪草苷的抗菌作用及其对实验性泌尿系统感染的疗效", 创新药物及新品种研究、开发学术研讨会论文集, pages 320 - 324 * |
| 江湛等: "姜黄素对粪肠球菌生物膜的影响", 口腔生物医学, vol. 8, no. 4, pages 199 - 201 * |
| 潘虹等: "壳聚糖改性及其在抗菌方面的应用", 纺织学报, vol. 32, no. 2, pages 96 - 101 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moradpoor et al. | An overview of recent progress in dental applications of zinc oxide nanoparticles | |
| DE60021603T2 (en) | USE OF TOOTH PRESERVATIVES FOR TOOTH STONE CONTROL | |
| DE69917285T2 (en) | STABILIZED COMPOSITIONS WITH ANTIBACTERIAL EFFICACY | |
| EP0396411A2 (en) | Denture stabilizing compositions | |
| JPH0215014A (en) | Cement composition containing poly (vinyl phosphonic acid) | |
| US20020198283A1 (en) | Calcium hydroxide-based root canal filling material | |
| US20180280431A1 (en) | Process for Obtaining the Product for Prevention, Interruption of Dental Caries Lesions and Teeth Remineralization and Obtained Product | |
| CN113576961A (en) | Agilawood toothpaste and preparation method thereof | |
| CN114099787B (en) | Absorbable biological membrane, preparation method and application thereof | |
| CN115350116A (en) | Oral cavity antibacterial cream and preparation method and application thereof | |
| JP6474530B2 (en) | Orthodontic complex and method for producing the same | |
| CN103800210B (en) | A kind of dentistry containing protease, department of stomatology preparation and preparation method thereof | |
| CN110302067B (en) | Adjuvant with tooth whitening and repairing functions and preparation method thereof | |
| CN111820239A (en) | Liquid composition and preparation method and application thereof | |
| JP6474531B2 (en) | Orthodontic member and manufacturing method thereof | |
| Dako et al. | The use of calcium hydroxide as an intracanal medicament in the treatment of large periapical lesions. A review | |
| US6585514B2 (en) | Solubilizing agent of carbonated calcium hydroxide-based root canal filler and solubilizing method | |
| CN114957511B (en) | Algin oligosaccharide zinc and preparation method and application thereof | |
| CZ283600B6 (en) | Mixed salt of copolymer of alkylvinyl ether containing 1 to 4 carbon atoms in the alkyl moiety with maleic acid and preparation in which the salt is comprised | |
| CN114948765B (en) | Mouthwash and preparation method thereof | |
| CN115252777B (en) | In-situ whitening caries-preventing gel and preparation method thereof | |
| CN114796260B (en) | Oral care composition and preparation method thereof | |
| EP2392315B1 (en) | Conditioning composition for treatment of dental implant surfaces | |
| CN117100620A (en) | Oral root canal inner sealing medicine, preparation method and application thereof | |
| CN117285662A (en) | Chitosan bipyridine quaternary ammonium salt and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |